MarketFriction

Unjha Formulations Ltd

BSE 531762 · Pharmaceuticals
₹33.00 +1.54%
BSE close2026-10-01
Market cap₹14.1 Cr.
P/E29.4

Price

Drag to pan, scroll or pinch to zoom. Ruler (or Shift + drag) measures a move.Dashed lines: 52 week high and low. Prices adjusted for splits and bonuses.

Financials

Standalone, Rs crore
Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026
Sales4.765.554.433.953.783.762.443.634.294.443.333.31
Expenses4.875.144.373.233.893.522.703.213.504.163.783.12
Operating Profit-0.110.410.060.72-0.110.24-0.260.420.790.28-0.450.19
OPM %-2.31%7.39%1.35%18.23%-2.91%6.38%-10.66%11.57%18.41%6.31%-13.51%5.74%
Other Income0.010.000.010.000.020.010.000.000.060.000.000.00
Interest0.000.000.050.000.000.000.000.000.000.000.000.00
Depreciation0.020.020.020.020.020.020.030.030.030.040.040.04
Profit before tax-0.120.390.000.70-0.110.23-0.290.390.820.24-0.490.15
Tax %0.00%0.00%0.00%0.00%0.00%41.38%0.00%0.00%0.00%51.02%0.00%
Net Profit-0.120.39-0.180.70-0.110.22-0.410.390.820.24-0.740.16
EPS in Rs-0.270.87-0.401.56-0.250.49-0.920.871.830.54-1.650.36
Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026TTM
Sales10.3612.2311.3011.2810.599.9614.1613.1518.5013.8615.5915.37
Expenses10.0011.8610.9610.9810.349.8313.8412.7117.9313.3414.6414.56
Operating Profit0.360.370.340.300.250.130.320.440.570.520.950.81
OPM %3.47%3.03%3.01%2.66%2.36%1.31%2.26%3.35%3.08%3.75%6.09%5.27%
Other Income0.080.110.040.100.260.220.190.030.010.110.160.06
Interest0.100.100.020.010.120.170.130.060.050.010.010.00
Depreciation0.080.090.100.090.080.080.080.080.080.100.140.15
Profit before tax0.260.290.260.300.310.100.300.330.450.520.960.72
Tax %0.00%0.00%0.00%0.00%0.00%0.00%16.67%15.15%40.00%23.08%26.04%
Net Profit0.260.300.260.300.310.100.250.280.280.410.700.48
EPS in Rs0.580.670.580.670.690.220.560.620.620.921.561.08
Dividend Payout %0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%
10 Years5 Years3 YearsTTM1 YearLast Year
Compounded Sales Growth4%9%6%13%
Compounded Profit Growth10%48%36%433%
Stock Price CAGR12%23%20%27%
Return on Equity16%14%15%20%
Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Equity Capital4.484.484.484.484.484.484.484.484.484.484.484.48
Reserves-4.09-3.83-3.54-3.27-2.97-2.67-2.56-2.31-2.03-1.75-1.34-0.64
Borrowings0.400.000.050.000.000.000.000.000.000.000.000.00
Other Liabilities2.512.282.792.752.151.901.611.280.962.201.421.67
Total Liabilities3.302.933.783.963.663.713.533.453.414.934.565.51
Fixed Assets1.091.031.221.161.121.141.121.071.101.121.201.30
CWIP0.000.000.000.000.000.000.000.000.000.000.000.00
Investments0.000.000.000.000.000.000.000.000.000.000.000.00
Other Assets2.211.902.562.802.542.572.412.382.313.813.364.21
Total Assets3.302.933.783.963.663.713.533.453.414.934.565.51
Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Cash from Operating Activity-0.700.410.390.14-0.120.39-0.700.28-0.261.03-0.041.24
Cash from Investing Activity-0.09-0.02-0.280.060.04-0.10-0.06-0.02-0.10-0.11-0.18-0.23
Cash from Financing Activity0.40-0.400.05-0.050.230.000.000.00-0.06-0.05-0.01-0.01
Net Cash Flow-0.38-0.010.150.150.160.29-0.770.25-0.420.86-0.231.00
Free Cash Flow-0.780.390.110.20-0.080.29-0.760.26-0.360.92-0.221.01
CFO/OP-368%114%105%41%-37%204%-408%88%-48%189%19%156%
Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Debtor Days28.0828.5419.4025.1943.3639.6435.9118.0429.1431.7639.7731.61
Inventory Days35.6222.7640.8339.4022.9221.3755.6034.0838.9229.5632.9219.10
Days Payable122.4894.3598.20106.2287.5082.7977.3539.8132.1047.8537.3939.71
Cash Conversion Cycle-58.78-43.06-37.97-41.63-21.22-21.7914.1612.3135.9713.4735.2910.99
Working Capital Days-46.66-28.19-24.17-21.96-8.41-9.3122.7217.2737.1914.6034.2421.31
ROCE %37.62%50.00%47.56%25.45%22.79%25.90%14.48%21.03%16.88%19.31%18.06%27.79%
Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026
Promoters36.92%36.92%36.92%36.92%36.92%36.92%36.92%36.92%36.92%36.92%36.92%36.92%
Public63.08%63.08%63.08%63.08%63.07%63.07%63.07%63.08%63.08%63.08%63.08%63.07%
No. of Shareholders3,9934,0123,9333,9853,9694,2084,2734,2134,2844,2514,2354,223

Fundamentals

Market Cap₹ 14.1 Cr.
Current Price₹ 31.5
Stock P/E29.4
Book Value₹ 8.57
ROCE27.8 %
ROE20.1 %
Dividend Yield0.00 %
Face Value₹ 10.0
Compounded Sales Growth (TTM)13%
Compounded Profit Growth (TTM)433%
Standalone figures.
Valuation
Market capRs 15 Cr
Enterprise valueRs 13 Cr
P/E (TTM)30.80x
Price to book3.85x
Price to sales0.96x
EV / EBITDA14.94x
EV / EBIT18.01x
EV / sales0.86x
Price to cash flow11.92x
Earnings yield3.25%
P/E, 3-year average22.36x
P/B, 3-year average2.86x
P/E, 5-year average20.78x
P/B, 5-year average2.56x
Profitability
Operating margin (excl. other income)6.09%
Operating margin (incl. other income)7.12%
EBITDA margin5.73%
Pre-tax margin4.68%
Net profit margin3.12%
Net margin, latest quarter4.83%
ROE20.06%
ROCE27.79%
ROA13.90%
ROE, 3-year average14.95%
ROCE, 3-year average21.72%
ROA, 3-year average9.75%
ROE, 5-year average13.84%
ROCE, 5-year average20.61%
ROA, 5-year average8.92%
ROIC (approx.)24.54%
Tax rate26.04%
Other income / net worth4.17%
Growth
Sales growth (latest year)12.48%
Profit growth (latest year)70.73%
Sales CAGR, 3 years5.84%
Sales CAGR, 5 years9.37%
Profit CAGR, 3 years35.72%
Profit CAGR, 5 years47.58%
Sales growth QoQ-0.60%
Sales growth YoY (latest quarter)-8.82%
Profit growth YoY (latest quarter)-58.97%
Per share
EPS (TTM)Rs 1.07
EPS (latest year)Rs 1.56
EPS (latest quarter)Rs 0.36
EPS, 3-year averageRs 1.03
EPS, 5-year averageRs 0.86
Book value per shareRs 8.57
Sales per shareRs 34.30
Cash flow per shareRs 2.77
Free cash flow per shareRs 2.25
Efficiency
Asset turnover2.83x
Fixed asset turnover11.99x
Inventory turnover19.62x
Inventory days19 days
Debtor days32 days
Debtors turnover11.55x
Creditor days40 days
Cash conversion cycle11 days
Working capital days21 days
Leverage
Cash and bankRs 2 Cr
Net debtRs -2 Cr
Net debt / EBITDA-1.86x
Interest coverage73.00x
Owners' fund to total sources69.69%
Cash flow
Cash from Operating Activity (latest year)Rs 1 Cr
Cash from Investing Activity (latest year)Rs -0 Cr
Cash from Financing Activity (latest year)Rs -0 Cr
Net Cash Flow (latest year)Rs 1 Cr
Free cash flow (latest year)Rs 1 Cr
Cash from ops / profit, 5 years1.17x
Sales to cash flow12.57x
Statement figures
Net sales (TTM)Rs 15 Cr
Net sales (latest year)Rs 16 Cr
Sales (latest quarter)Rs 3 Cr
Operating profit excl. other income (latest year)Rs 1 Cr
Operating profit (latest quarter)Rs 0 Cr
Other income (TTM)Rs 0 Cr
EBITDA (TTM)Rs 1 Cr
PBDT (TTM)Rs 1 Cr
Profit before tax (TTM)Rs 1 Cr
Tax (latest year)Rs 0 Cr
Net profit (TTM)Rs 0 Cr
Net profit (latest year)Rs 1 Cr
Net profit (latest quarter)Rs 0 Cr
Depreciation (TTM)Rs 0 Cr
Depreciation (latest quarter)Rs 0 Cr
Interest (TTM)Rs 0 Cr
Cost of goods sold (latest year)Rs 12 Cr
Total expenditure (latest year)Rs 15 Cr
Total income (latest year)Rs 16 Cr
Share capitalRs 4 Cr
ReservesRs -1 Cr
Shareholders' fundsRs 4 Cr
Total assetsRs 6 Cr
Net blockRs 1 Cr
ReceivablesRs 1 Cr
InventoryRs 1 Cr
Other liabilitiesRs 2 Cr
Shares outstanding (crore)0.45
Ownership
Promoter holding36.92% (+0.00 in a year)
Computed by MarketFriction from the standalone statements. Returns use average balances.
P/E 30.8 is at the 76th percentile of its own 9.4-year range (median 18.2, low 8.2, high 124.5).
P/B 3.85 is at the 80th percentile (median 2.96).
Monthly. Market cap from split-adjusted price; profit and book value as reported by that month. A low percentile means cheap versus its own history, not cheap versus peers.
Period531762Nifty 50Difference
1 week+8.2%-2.8% +11.0 pts
1 month+32.6%-6.8% +39.4 pts
3 months+66.2%-7.6% +73.9 pts
3 years+82.8%+14.2% +68.7 pts
5 years+200.0%+27.9% +172.1 pts

Red flags

F-score 7 of 8
No red flags in the latest statements and filings.
Checks on the latest reported years: cash vs profit, accruals, receivables and inventory vs sales, dilution, debt, interest cover, equity, other income, losses, and auditor, top-management, insolvency and regulator filings in the last 12 months. A flag asks for an explanation; it is not a verdict.

Latest quarter

Jun 2026
Sales ₹3 Cr -8.8% vs Jun 2025. Net profit ₹0 Cr -59.0%.

Activity

Compare
CompanyMcap (Cr)P/EROCE
Sun Pharmaceutical Industries Ltd447,47635.420.5 %
Divis Laboratories Ltd250,36384.022.0 %
Torrent Pharmaceuticals Ltd186,15283.415.2 %
Zydus Lifesciences Ltd119,75024.621.1 %
Cipla Ltd111,43031.115.5 %
Laurus Labs Ltd106,92897.817.8 %
Mankind Pharma Ltd105,12049.313.5 %
Dr Reddys Laboratories Ltd104,49432.413.0 %
Aurobindo Pharma Ltd97,68225.812.9 %
Lupin Ltd93,84015.829.9 %
Glenmark Pharmaceuticals Ltd68,90522.139.8 %
Alkem Laboratories Ltd62,77227.621.2 %
Biocon Ltd61,43984.53.61 %
Abbott India Ltd57,94935.944.8 %
Gland Pharma Ltd49,33343.115.1 %
No bulk or block deals on record.
No corporate actions on record.
No announcements in our files yet.
Company filings to NSE, newest first. Routine notices (trading window, newspaper copies) are left out. Click a row for the filing.
No short selling reported to NSE in our files.
Short sales disclosed by brokers to NSE, by trade date. Collected since late September 2026.
Not on any NSE surveillance list in the latest file.

Quick answers

What is the market cap of Unjha Formulations Ltd?

Unjha Formulations Ltd (531762) has a market capitalisation of Rs 14.1 Cr. at the 2026-10-01 close.

What is the P/E ratio of Unjha Formulations Ltd?

Unjha Formulations Ltd trades at a P/E of 29.4 on trailing twelve-month profit, at the 2026-10-01 close.

What were Unjha Formulations Ltd's latest quarterly results?

In the Jun 2026 quarter, Unjha Formulations Ltd sales was Rs 3 Cr (-8.8% vs Jun 2025) and net profit was Rs 0 Cr.

Data: NSE and BSE daily reports, company filings. Numbers only, not investment advice, not a SEBI-registered research service.AboutMethodologyFAQResearchContactTermsPrivacyDisclaimerUpdated 2026-10-03